A study has revealed four classes of antibodies that can neutralise Omicron by targeting one of four areas of the spike protein present in SARS-CoV-2 variants.
List view / Grid view
A nasal spray of the COVID-19 Vaccine Oxford/AstraZeneca was found to protect hamsters and monkeys against SARS-CoV-2 in an NIH study.
In mice and hamsters, therapies made from two antibodies were found to be mostly effective against a range of SARS-CoV-2 variants.
Neutralisation resistance generated by Spike (S) protein mutations in Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) poses a challenge to antibody therapies for COVID-19. Antibody cocktails targeting the S protein receptor binding domain (RBD) are one way to avoid viral neutralisation escape, however only certain antibody combinations are currently effective.…
With a return to the workplace on the horizon for an increasing number of scientists, Richard Goodwin considers how COVID-19 will impact the ways research is conducted. One outcome he posits is the acceleration of the digital transformation that was already occurring in pharmaceutical R&D.
The UK has launched the Pandemic Preparedness Partnership which will advise the G7 Presidency how to reduce vaccine development time from 300 to 100 days.
A collaboration between academia and industry has produced an assay and new screening technique which utilises directed evolution for the discovery of antibody-based drugs.
To reach the full potential of artificial intelligence (AI) in the pharma industry, it is essential that companies harmonise their data to remove the need for unnecessary human intervention. This article outlines how companies are working towards digital maturation and the obstacles they need to overcome to ensure the value…
Advances in informatics have afforded researchers the ability to extrapolate petabytes of human genomics data and translate it into biologically relevant information. However, further translating this information into knowledge can prove challenging. Slavé Petrovski, Vice President and Head of Genome Analytics and Bioinformatics for AstraZeneca’s Centre for Genomics Research, spoke…
The future of drug discovery lies in an automated world where the workflows for biological assays, chemical synthesis and data analysis are connected by flexible, mobile and modular hardware, integrated with software solutions that will interface with scientists for increased efficiency and productivity (the realisation of Industry 4.0). This article…
On 5-6 November, ACC Liverpool hosted the ELRIG Drug Discovery event, which allowed R&D professionals to come together and discuss the latest industry developments.
AI has applications in many areas of research, including genomics. Slavé Petrovski of AstraZeneca reveals how AI is used in the study of the human genome and how it may evolve in the future.
Claus Bendtsen at AstraZeneca reveals how AI can be used to improve our understanding of disease, to help identify the causes of conditions and aid in drug discovery.
A new AI project marks the first time 10 pharmaceutical companies have agreed to share data to aid drug discovery.